We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical
CPRX

52 hedge funds and large institutions have $78.7M invested in Catalyst Pharmaceutical in 2014 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more call options, than puts

Call options by funds: $1.54M | Put options by funds: $656K

39% more capital invested

Capital invested by funds: $56.4M → $78.7M (+$22.3M)

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

11% more funds holding

Funds holding: 47 → 52 (+5)

Holders
52
Holders Change
+5
Holders Change %
+10.64%
% of All Funds
1.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
12
Reduced
10
Closed
13
Calls
$1.54M
Puts
$656K
Net Calls
+$883K
Net Calls Change
+$816K

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$11.7M
2
Morgan Stanley
Morgan Stanley
New York
+$3.23M
3
SFM
Sphera Funds Management
Israel
+$1.79M
4
TC
TFS Capital
Pennsylvania
+$599K
5
Renaissance Technologies
Renaissance Technologies
New York
+$514K

Top Sellers

1
O
OrbiMed
New York
-$4.79M
2
PA
Perceptive Advisors
New York
-$3.79M
3
BC
Broadfin Capital
New York
-$2.61M
4
SC
Sophrosyne Capital
New York
-$1.52M
5
GTC
Ghost Tree Capital
New York
-$1.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
ARTA
26
A.R.T. Advisors
New York
$206K +$162K +62,081 New
Nomura Holdings
27
Nomura Holdings
Japan
$181K +$77.5K +29,640 +119%
State Street
28
State Street
Massachusetts
$164K +$5.75K +2,200 +5%
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
$154K – – –
Jane Street
30
Jane Street
New York
$153K +$120K +46,039 New
CS
31
Credit Suisse
Switzerland
$151K +$119K +45,384 New
CPA
32
Cowen Prime Advisors
New York
$143K -$5.03K -1,925 -4%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$137K – – –
FANJ
34
Financial Architects (New Jersey)
New Jersey
$100K – – –
WPP
35
Whalerock Point Partners
Rhode Island
$100K +$79.4K +30,400 New
RCM
36
Rotella Capital Management
Washington
$76K +$23.7K +9,052 +66%
HCM
37
Highbridge Capital Management
New York
$70K +$54.9K +20,998 New
AL
38
Agran Libbie
California
$66K +$52.3K +20,000 New
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$51K -$242K -92,638 -86%
Goldman Sachs
40
Goldman Sachs
New York
$41K +$31.9K +12,220 New
NCCM
41
Nine Chapters Capital Management
New Jersey
$36K +$28.5K +10,900 New
BIM
42
BlackRock Investment Management
Delaware
$34K +$1.07K +408 +4%
Citigroup
43
Citigroup
New York
$34K +$17.1K +6,558 +185%
Janney Montgomery Scott
44
Janney Montgomery Scott
Pennsylvania
$33.2K – – –
Creative Planning
45
Creative Planning
Kansas
$27K – – –
ST
46
Spot Trading
Illinois
$26K +$20.3K +7,785 New
FNYS
47
First New York Securities
New York
$24.9K +$19.6K +7,500 New
BIT
48
BlackRock Institutional Trust
California
$16K +$12.5K +4,782 New
VIA
49
Vantage Investment Advisors
Pennsylvania
$10K – – –
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$7K – – –
1
2
3

CPRX Hedge Fund Activity: Q3 2014 in Review

52 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2014, worth a combined $78.7M — up 39% from $56.4M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CPRX positions and 13 closed out — a net gain of 5 holders — while 12 added to existing stakes and 10 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $11.7M. The largest seller was OrbiMed, exiting entirely with an estimated $4.79M sold.

  • 52 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2014, up from 47 in Q2 2014.
  • Funds reported $78.7M of Catalyst Pharmaceutical stock for Q3 2014, up 39% quarter-over-quarter.
  • 18 funds opened new Catalyst Pharmaceutical positions in Q3 2014 and 13 closed out, a net change of +5 holders.
  • The largest Catalyst Pharmaceutical buyer in Q3 2014 was Baker Bros. Advisors, an estimated $11.7M added.
  • The largest Catalyst Pharmaceutical seller in Q3 2014 was OrbiMed, an estimated $4.79M sold.

Based on aggregated 13F filings for Q3 2014.